Interim report Q3 2024 is now available
Sveinn Sölvason, President and CEO, comments:
“We delivered solid sales in the third quarter amounting to USD 214 million. Organic sales growth was 7%. The strong momentum we have seen in EMEA throughout 2024 continued in Q3 driven by strong performance in Prosthetics & Neuro Orthotics and Patient Care. Our profitability was strong for the quarter with an EBITDA margin of 22%.”
Embla Medical will host a conference call on October 22, 2024, at 09:00 CET / 7:00 GMT / 3:00 EST. A webcast can be accessed by clicking the following link: Embla Medical Q3 2024 webcast
To actively participate in the Q&A session during the call please use following link: Registration form for Conference Call Q&A
Download Company Announcement PDF
Download Investor Presentation PDF
Latest Announcements and News
Announcements
Recent IR News
A Record-Breaking Partnership between Össur and Nissan
Team Össur member and Nissan Ambassador – Paralympic god medalist Richard Whitehead – set a new World Record at yesterday‘s 2024 Chicago Marathon.
This was Richard‘s 80th marathon, and he prepared for the race using his Össur running prosthetics and a specially adapted Nissan ARIYA.
Share Information and Results
Share Information
Financial Calendar and Events
Email Subscription
To stay up-to-date with our latest investor email alerts, please sign up.
General Inquiries
Klaus Sindahl, Head of Investor Relations
Email: [email protected]
Telephone number: +4553630134